Gefitinib (Iressa) received FDA approval in 2003 as third-line treatment for metastatic non–small-cell lung cancer (mNSCLC). In phase 3 trials, the tyrosine kinase inhibitor shrunk tumors in only 11% of the efficacy population, but the change in that 11% was dramatic enough to warrant approval.
When Alexander Graham Bell phoned it in, so to speak, who could have predicted that it would eventually lead to IBM’s Watson Health tackling medication adherence with state-of-the-art analytics?
Information overload from a flood of new diagnostics forces insurers to ramp up prior authorization and utilization review.
Michael Sherman, MD
Manufacturers are starting to offer significant rebates in exchange for preferred status on an insurer’s formulary.
Steven Pearson, MD, ICER
A Harvard Law School group is among those that have taken action.
Managed care organizations need to work on several fronts if they are to improve patient adherence. Limiting out-of-pocket costs is one place to start.
Sarepta’s eteplirsen functions like an RNA patch so functioning dystrophin gets made. Other drugs like it may be used to treat Ebola and other viral infections.